SCHEMBL49121

SCHEMBL49121

[CH2]OCCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646872 0.90
SCHEMBL14892586 0.87
SCHEMBL14892156 0.87
SCHEMBL8459020 0.87 LMNA (0.38)
SCHEMBL158305 0.77
SCHEMBL6685284 0.76
SCHEMBL9344473 0.72 ALDH1A1 (0.30)
SCHEMBL10501174 0.72 ALDH1A1 (0.30)
SCHEMBL28818190 0.71
SCHEMBL15112 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3594248-B1 HYDROXYPROPYL METHYL CELLULOSE HARD CAPSULES AND PROCESS OF MANUFACTURE CAPSUGEL BELGIUM NV (BE) 2021-08-04 EP claimed
US-20200138723-A1 HYDROXYPROPYL METHYL CELLULOSE HARD CAPSULES AND PROCESS OF MANUFACTURE CAPSUGEL BELGIUM NV (BE) 2020-05-07 US claimed
US-9655860-B2 Hydroxypropyl methyl cellulose hard capsules and process of manufacture CAPSUGEL BELGIUM NV (BE) 2017-05-23 US claimed
US-20170087092-A1 HYDROXYPROPYL METHYL CELLULOSE HARD CAPSULES AND PROCESS OF MANUFACTURE CAPSUGEL BELGIUM NV (BE) 2017-03-30 US claimed
US-20160067188-A1 HYDROXYPROPYL METHYL CELLULOSE HARD CAPSULES AND PROCESS OF MANUFACTURE CAPSUGEL BELGIUM NV 2016-03-10 US claimed
US-20150164854-A1 FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF PHARMACYCLICS LLC 2015-06-18 US claimed
WO-2013066833-A1 COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES GLAXOSMITHKLINE LLC (US) 2013-05-10 WO claimed
US-20110021528-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2011-01-27 US claimed
WO-2010123507-A1 TREATMENT OF NON-LOCALIZED INFLAMMATION WITH PAN-HDAC INHIBITORS PHARMACYCLICS, INC. (US) 2010-10-28 WO claimed
US-20100168410-A1 Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture PFIZER PRODUCTS INC. (US) 2010-07-01 US claimed
US-20080004331-A1 for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition PHARMACYCLICS, INC. (US) 2008-01-03 US claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070293540-A1 for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition PHARMACYCLICS, INC. 2007-12-20 US claimed
US-7276612-B2 For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides PHARMACYCLICS, INC. (US) 2007-10-02 US claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
EP-1611088-A2 HYDROXAMATES AS THERAPEUTIC AGENTS AXYS PHARMACEUTICALS, INC. (US) 2006-01-04 EP claimed
WO-2005097770-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS, INC. (US) 2005-10-20 WO claimed
US-20050227976-A1 Novel hydroxamates as therapeutic agents AXYS PHARMACEUTICALS, INC. (US) 2005-10-13 US claimed
US-20050187261-A1 For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine AXYS PHARMACEUTICALS, INC. (US) 2005-08-25 US claimed
WO-2004092115-A2 HYDROXAMATES AS THERAPEUTIC AGENTS AXYS PHARMACEUTICALS INC. (US) 2004-10-28 WO claimed